Improved peptide-based inhibitors of human
tryptase
were discovered using informationgleaned from tripeptide library screening and structure-guided design methods, including fragment screening.Our efforts sought to improve this class of inhibitors by replacing the traditional Lys or Arg P1 element.The optimized compounds display lo
w nanomolar potency against the mast cell target and several hundred-fold selectivity
with respect to serine protease off targets. Thus, replacement of Lys/Arg at P1 in a peptide-like scaffold does not need to be accompanied by a loss in target affinity.